Bruce Booth Sells 467,878 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the sale, the director owned 472,267 shares of the company’s stock, valued at approximately $52,086,327.43. The trade was a 49.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 29th, Bruce Booth sold 45,367 shares of Kymera Therapeutics stock. The stock was sold at an average price of $107.06, for a total value of $4,856,991.02.
• On Monday, June 29th, Bruce Booth sold 31,283 shares of Kymera Therapeutics stock. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84.
• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total transaction of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total transaction of $30,305,683.43.
• On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total transaction of $13,540,707.20.
• On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.98, for a total transaction of $140,771.84.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total transaction of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.01, for a total transaction of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.

Kymera Therapeutics Stock Performance

KYMR traded up $5.35 on Tuesday, hitting $114.67. 1,134,754 shares of the company were exchanged, compared to its average volume of 766,343. The firm has a fifty day simple moving average of $85.27 and a two-hundred day simple moving average of $82.38. The stock has a market capitalization of $9.43 billion, a PE ratio of -32.12 and a beta of 2.02. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, equities analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently modified their holdings of the stock. SG Americas Securities LLC boosted its position in Kymera Therapeutics by 169.1% during the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after acquiring an additional 14,261 shares in the last quarter. Hudson Bay Capital Management LP raised its position in shares of Kymera Therapeutics by 362.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after acquiring an additional 18,134 shares in the last quarter. Eagle Health Investments LP purchased a new position in shares of Kymera Therapeutics in the 4th quarter valued at approximately $10,606,000. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the period. Finally, State of New Jersey Common Pension Fund D bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $2,610,000.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $134.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Jefferies Financial Group began coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price target for the company. UBS Group increased their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Truist Financial lifted their price objective on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $121.41.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.